VectorY Therapeutics has secured €129m ($138m) in a Series A funding round to progress the development of its vectorised antibody programmes in neurodegenerative diseases. EQT Life Sciences and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback